Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2025-08-29 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
OVERSEAS REGULATORY ANNOUNCEMENT ANNOUNCEMENT TO CREDITORS
Transaction in Own Shares Classification · 1% confidence The document is an overseas regulatory announcement under HKEX Rule 13.10B, detailing the Company’s plan to repurchase its H shares under a general mandate and reduce its registered capital, and notifying creditors of their rights. This is not a financial report or regular earnings announcement but a share repurchase (transaction in own shares) notification. Therefore, it falls under the “Transaction in Own Shares” category (POS).
2025-08-29 English
INSIDE INFORMATION ANNOUNCEMENT ON THE PLANS FOR THE REPURCHASE OF SHARES BY WAY OF CENTRALISED PRICE BIDDING
Transaction in Own Shares Classification · 1% confidence The document is a detailed announcement of the Company’s plans to repurchase its own A and H shares, including the legal basis, maximum number and price of shares to be repurchased, funding source, implementation procedures, and impacts on shareholding structure. This clearly falls under a transaction in own shares (share repurchase) and matches the definition of code POS.
2025-08-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 1% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-08-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 1% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-08-29 English
CONNECTED TRANSACTION ACQUISITION OF 70% EQUITY INTEREST IN POWER SALES BY WAY OF CAPITAL INCREASE
M&A Activity Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement detailing a connected transaction under Chapter 14A Listing Rules whereby the company’s subsidiary subscribes for additional registered capital to acquire a 70% equity interest in Power Sales. It is not a full financial report or earnings release but a transaction announcement involving an equity acquisition via capital increase. This falls squarely under M&A Activity (Code: TAR).
2025-08-29 English
Interim dividend for the six months ended 30 June 2025
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement filed on the Hong Kong Exchange under the EF001 template, titled “Interim dividend for the six months ended 30 June 2025.” It details the dividend type (Interim), dividend amount per share, key dates (ex-dividend, record, payment), currency, withholding tax rates, and related shareholder information. This aligns with a Notice of Dividend Amount rather than a full financial report or other announcement type.
2025-08-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.